Interestingly, different from the prognosis value of CDK4 amplification in dedifferentiated liposarcoma and glioblastoma patients, we demonstrated that CDK4 amplification was associated with a better DFS (P = 0.016) and OS (P = 0.023) (Figure 2). The gene discussed is CDK4; the disease is glioblastoma.